Notice of Intent to Publish a Funding Opportunity Announcement for Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R21 - Clinical Trial Optional)
ID: 355536Type: Forecasted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/355536
Timeline
    Description

    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at enhancing the understanding of the neurological effects associated with infection-related chronic illnesses, including conditions such as Neuro-PASC, post-treatment Lyme Disease, and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The initiative encourages applications that explore the neurological and psychiatric manifestations of these illnesses, with a particular interest in projects that may investigate common neuropsychiatric mechanisms across multiple conditions, although single-condition studies are also welcome. This funding opportunity, utilizing the R21 activity code, is expected to be announced in Fall 2024, with applications due in Winter 2025, and an estimated award date set for December 1, 2025. Interested applicants should prepare to collaborate and develop responsive projects in advance of the anticipated timeline.

    Point(s) of Contact
    No information provided.
    Files
    No associated files provided.
    Similar Opportunities
    Notice of Intent to Publish a Funding Opportunity Announcement for Towards a Better Understanding of the Neurological Effects of Infection-Associated Chronic Illnesses (R01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for research focused on the neurological effects of infection-associated chronic illnesses, including conditions like Neuro-PASC, post-treatment Lyme Disease, and ME/CFS. This initiative aims to promote understanding of the neuropsychiatric manifestations of these illnesses, with a particular interest in projects that explore common mechanisms across multiple conditions, although applications can focus on individual illnesses as well. The anticipated funding amount for this grant is up to $500,000, with the NOFO expected to be published in Fall 2024 and applications due in Winter 2025. Interested applicants should prepare to submit their proposals by the estimated closing date of February 3, 2025, with awards expected to be made by December 1, 2025.
    Notice of Intent to Publish a Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) as part of the Rare Diseases Clinical Research Network (RDCRN). This initiative aims to solicit applications for collaborative, multi-site research focused on advancing the diagnosis, management, and treatment of rare diseases, with an emphasis on addressing unmet clinical trial readiness needs. The funding, estimated at $1 million, will support specialized centers through cooperative agreements, with the NOFO expected to be published in winter 2024 and applications due in summer 2024. Interested applicants should prepare to develop meaningful collaborations, as the estimated award date is set for July 1, 2025.
    Clinical Trial Readiness for Functional Neurological Disorders (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for a funding opportunity titled "Clinical Trial Readiness for Functional Neurological Disorders (U01 Clinical Trial Optional)," aimed at enhancing clinical trial methodologies for Functional Neurological Disorders (FNDs). This initiative seeks to address critical challenges in the diagnosis and management of FNDs by encouraging the validation of biomarkers and clinical outcome assessments (COAs) that are specifically tailored for clinical trials. Given the significant healthcare burden posed by FNDs, which often require interdisciplinary approaches for effective management, this funding opportunity emphasizes the need for robust clinical evidence to improve treatment strategies and patient outcomes. Interested applicants, including a diverse range of organizations such as higher education institutions and community-based organizations, must submit their proposals by November 5, 2024, with funding contingent on NIH appropriations. For further inquiries, applicants can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Notice of Intent to Publish a Funding Opportunity Announcement for Morris K. Udall Discovery Centers without Walls (DCWoW) for Parkinson's Disease Research (RM1 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the Morris K. Udall Discovery Centers without Walls (DCWoW) aimed at advancing research into Parkinson's Disease (PD). This initiative seeks to promote collaborative team science research to uncover the causes of PD, a chronic and progressive movement disorder affecting over half a million individuals in the U.S., along with their caregivers. The NOFO is expected to be released in autumn 2024, with applications due in early spring 2025, and will utilize the RM1 activity code. Interested applicants are encouraged to develop collaborative projects, as the estimated award date is set for December 1, 2025, with no cost-sharing or matching requirements.
    Notice of Intent to Publish a Funding Opportunity Announcement for Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Funding Opportunity Announcement (FOA) for the Blueprint Neurotherapeutics Network (BPN), focusing on biologic-based drug discovery and development for disorders of the nervous system. This initiative aims to solicit applications from researchers working on diverse biotherapeutic modalities, including antibodies, peptides, proteins, oligonucleotides, gene therapies, and cell therapies, to address various nervous system disorders. The anticipated FOA is expected to be released in Fall 2024, with applications due in Winter 2025, and will utilize the U44 activity code. Interested applicants should prepare for collaboration and project development, as the estimated award date is set for December 1, 2025. For further details, potential applicants can refer to the NIH website or contact the agency directly.
    Mechanisms of Reciprocal Interactions between HIV Associated Neuroinflammation and CNS Persistence: Implications in HIV Neuropathogenesis and Cure (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanisms of Reciprocal Interactions between HIV Associated Neuroinflammation and CNS Persistence: Implications in HIV Neuropathogenesis and Cure (R01 Clinical Trial Not Allowed)." This initiative aims to investigate the mechanisms underlying the interactions between HIV-associated neuroinflammation and the persistence of HIV in the central nervous system (CNS), despite effective antiretroviral therapy, with a focus on developing novel therapeutic strategies. The program encourages the use of advanced methodologies, including human tissue samples, organoid models, and single-cell technologies, to explore the dynamics of CNS reservoirs and associated co-morbidities. A total of $4.5 million is available to fund 8-10 awards in fiscal year 2025, with applications due by November 9, 2024. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-25-180.html.
    Mechanisms of Reciprocal Interactions between HIV Associated Neuroinflammation and CNS Persistence: Implications in HIV Neuropathogenesis and Cure (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Exploratory/Developmental Research Grant to investigate the mechanisms of reciprocal interactions between HIV-associated neuroinflammation and central nervous system (CNS) persistence. This initiative aims to explore the roles of defective proviruses, viral proteins, and immune responses in the context of HIV-related CNS co-morbidities, encouraging innovative research methodologies and collaborative multidisciplinary approaches. A total of $4.5 million is available for 8-10 awards, with each project eligible for a maximum budget of $275,000 over two years. Applications are due by November 9, 2024, and interested parties can contact NIH Grants Information at grantsinfo@nih.gov for further inquiries or visit the opportunity announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-25-181.html.
    Global Brain and Nervous System Disorders Research Across the Lifespan (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Global Brain and Nervous System Disorders Research Across the Lifespan (R21 Clinical Trial Optional)" aimed at fostering exploratory and developmental research on brain and nervous system disorders, particularly in low- and middle-income countries (LMICs). This initiative encourages collaborative research projects that span the life cycle and address the increasing burden of neurological conditions, with a focus on building sustainable research capacity and developing culturally appropriate diagnostic and treatment strategies. Eligible applicants include a diverse range of organizations, such as historically black colleges and universities, tribal governments, and foreign entities, with no cost-sharing requirement. The application deadline is December 9, 2024, and interested parties can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries. More details can be found in the full announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-098.html.
    Notice of Intent to Publish a Funding Opportunity Announcement for TMD Collaborative for IMproving PAtient-Centered Translational Research (TMD IMPACT) (U54 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the TMD Collaborative for Improving Patient-Centered Translational Research (TMD IMPACT), aimed at advancing research on Temporomandibular Disorders (TMD). This initiative seeks to establish a national, interdisciplinary collaborative that will enhance TMD research, improve clinical care, and train future researchers in the field. The funding opportunity will provide a total of $7 million, with an award ceiling of $3.5 million for up to two cooperative agreements, and is expected to be published in Summer 2024, with applications due in Winter 2024. Interested applicants should prepare for the anticipated collaboration and project development in advance of the expected award date of July 1, 2025.
    Novel Preclinical Models of NeuroHIV in the cART Era (R61/R33 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Novel Preclinical Models of NeuroHIV in the cART Era" (Funding Opportunity Number: RFA-NS-24-035) aimed at developing innovative small animal models and human cellular systems that accurately reflect the interactions between the central nervous system (CNS) and the immune system in individuals living with HIV. This initiative seeks applications that propose the development and early-stage validation of next-generation humanized models to address cognitive and neurological impairments associated with chronic HIV infection, particularly in the context of antiretroviral therapy (ART). The total funding available for this initiative is approximately $6 million, with applications due by December 2, 2024. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.